Shang Hai Zheng Quan Bao·2025-12-07 18:54Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. has announced the inclusion of several of its products in the 2025 National Medical Insurance Directory and the newly established Commercial Health Insurance Innovative Drug Directory, which is expected to enhance drug accessibility and reduce patient medication costs [1][2]. Group 1: New Inclusion and Adjustments - The 2025 National Medical Insurance Directory and the Commercial Health Insurance Innovative Drug Directory will take effect on January 1, 2026 [1]. - Several listed products from the company have been newly included or have had their remarks adjusted in these directories [1]. Group 2: Financial Impact - The sales revenue of the newly included or adjusted drugs for the year 2024 and the first three quarters of 2025 is approximately RMB 401 million and RMB 892 million, respectively, accounting for about 0.98% and 3.04% of the company's total revenue during the same periods [2]. - The inclusion in these directories is expected to positively impact the company's future performance by promoting market sales and enhancing drug accessibility [2]. Group 3: Market Considerations - The specific sales performance of the pharmaceutical products will be influenced by factors such as medication demand, market competition, and sales channels, making the exact impact of the directory inclusion on future operating performance uncertain [2].